Maintenance Therapy in Oncology

Introduction to Maintenance Therapy

The National Comprehensive Cancer Network recommends maintenance therapy with reduced-intensity regimens for patients with metastatic disease achieving stable response after 6 cycles of chemotherapy, as it is superior to observation 1

For bladder cancer, the National Comprehensive Cancer Network recommends stopping chemotherapy at 6 cycles maximum, regardless of response status, as extending platinum-based combinations beyond this provides no survival benefit and increases toxicity 2, 3
For non-small cell lung cancer, the National Comprehensive Cancer Network recommends limiting platinum-doublet chemotherapy to 4-6 cycles, as continuation beyond this increases toxicity without survival benefit 4, 5, 6
For colorectal cancer, maintenance with fluoropyrimidine ± bevacizumab is the optimal strategy after 3-6 months of initial combination chemotherapy, showing significant progression-free survival benefit over observation 1
For ovarian cancer, current data do not support routine maintenance/consolidation treatment beyond 6 cycles of platinum-based chemotherapy 8
For pleural mesothelioma, continuation maintenance with pemetrexed after 4-6 cycles of pemetrexed-platinum is not recommended, as it shows no improvement in progression-free survival or overall survival compared to observation 9, 10

The American Society of Clinical Oncology suggests that patients must maintain good performance status (ECOG 0-1 or Karnofsky ≥50) after induction chemotherapy to be eligible for maintenance therapy 11
The National Comprehensive Cancer Network recommends re-evaluating patients after 2-3 cycles of induction chemotherapy, and continuing for 2 additional cycles to reach 4-6 cycle total if stable disease or response is achieved 2, 3, 11

The European Society for Medical Oncology recommends assessing response after 2-3 cycles of induction chemotherapy, and continuing for 2 additional cycles to reach 4-6 cycle total if stable disease or response is achieved 2, 3, 11
The National Comprehensive Cancer Network suggests using reduced-intensity single agents or doublets for maintenance therapy, rather than continuing full combination regimens 1
The American Society of Clinical Oncology recommends monitoring patients every 2-3 months during maintenance therapy, with clinical assessment and imaging to detect progression early 8
The National Comprehensive Cancer Network recommends proactive toxicity management to maintain quality of life and treatment adherence during maintenance therapy 1